Shao-Hsien Liu1, Jacob N Hunnicutt2, Christine M Ulbricht3, Catherine E Dubé3, Anne L Hume4,5, Kate L Lapane3. 1. Division of Epidemiology of Chronic Diseases and Vulnerable Populations, Department of Quantitative Health Sciences, University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA, 01605, USA. shaohsien.liu@umassmed.edu. 2. Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA. 3. Division of Epidemiology of Chronic Diseases and Vulnerable Populations, Department of Quantitative Health Sciences, University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA, 01605, USA. 4. Department of Family Medicine, Alpert Medical School, Brown University, Memorial Hospital of Rhode Island, Providence, RI, USA. 5. Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, USA.
Abstract
OBJECTIVES: Our objective was to describe the prevalence of adjuvants to opioid therapy and changes in these agents for pharmacologic management in nursing home residents with cancer. METHODS: We included Medicare beneficiaries with cancer and documented opioid use at nursing home admission in 2011-2013 (N = 3268). The Minimum Data Set 3.0 provided information on sociodemographic and clinical characteristics. Part D claims provided information on opioid and adjuvant use during the 7 days after admission and 90 days later. Proportions of changes in these agents were estimated. Separate logistic models estimated associations between resident characteristics and (1) use of adjuvants at admission and (2) intensification of pharmacologic management at 90 days. RESULTS: Nearly 20% of patients received adjuvants to opioids at admission, with gabapentin the most common adjuvant (34.4%). After 90 days, approximately 25% had maintained or intensified pharmacologic management. While advanced age (≥ 85 vs. 65-74 years, adjusted odds ratio [aOR] 0.80; 95% confidence interval [CI] 0.63-1.02) and comorbidities, including dementia (aOR 0.65; 95% CI 0.53-0.82) and depression (aOR 1.55; 95% CI 1.29-1.87), were associated with adjuvant use at admission, worse cognitive impairment (severe vs. no/mild, aOR 0.80; 95% CI 0.64-0.99) and presence of more severe pain (moderate/severe vs. no pain, aOR 1.60; 95% CI 1.26-2.03) were associated with intensification of drug regimen. CONCLUSION: Given aging-related changes and the presence of comorbid conditions in older adults, safety studies of these practices are warranted.
OBJECTIVES: Our objective was to describe the prevalence of adjuvants to opioid therapy and changes in these agents for pharmacologic management in nursing home residents with cancer. METHODS: We included Medicare beneficiaries with cancer and documented opioid use at nursing home admission in 2011-2013 (N = 3268). The Minimum Data Set 3.0 provided information on sociodemographic and clinical characteristics. Part D claims provided information on opioid and adjuvant use during the 7 days after admission and 90 days later. Proportions of changes in these agents were estimated. Separate logistic models estimated associations between resident characteristics and (1) use of adjuvants at admission and (2) intensification of pharmacologic management at 90 days. RESULTS: Nearly 20% of patients received adjuvants to opioids at admission, with gabapentin the most common adjuvant (34.4%). After 90 days, approximately 25% had maintained or intensified pharmacologic management. While advanced age (≥ 85 vs. 65-74 years, adjusted odds ratio [aOR] 0.80; 95% confidence interval [CI] 0.63-1.02) and comorbidities, including dementia (aOR 0.65; 95% CI 0.53-0.82) and depression (aOR 1.55; 95% CI 1.29-1.87), were associated with adjuvant use at admission, worse cognitive impairment (severe vs. no/mild, aOR 0.80; 95% CI 0.64-0.99) and presence of more severe pain (moderate/severe vs. no pain, aOR 1.60; 95% CI 1.26-2.03) were associated with intensification of drug regimen. CONCLUSION: Given aging-related changes and the presence of comorbid conditions in older adults, safety studies of these practices are warranted.
Authors: Camilla B Pimentel; Becky A Briesacher; Jerry H Gurwitz; Allison B Rosen; Marc T Pimentel; Kate L Lapane Journal: J Am Geriatr Soc Date: 2015-04 Impact factor: 5.562
Authors: Joseph Pergolizzi; Rainer H Böger; Keith Budd; Albert Dahan; Serdar Erdine; Guy Hans; Hans-Georg Kress; Richard Langford; Rudolf Likar; Robert B Raffa; Paola Sacerdote Journal: Pain Pract Date: 2008-05-23 Impact factor: 3.183
Authors: Shivani Shinde; Pamela Gordon; Prashant Sharma; James Gross; Mellar P Davis Journal: Support Care Cancer Date: 2014-08-29 Impact factor: 3.603
Authors: Todd B Monroe; Michael A Carter; Karen S Feldt; Mary S Dietrich; Ronald L Cowan Journal: Geriatr Gerontol Int Date: 2013-03-19 Impact factor: 2.730
Authors: Danni Zhao; Divya Shridharmurthy; Matthew J Alcusky; Yiyang Yuan; Anthony P Nunes; Anne L Hume; Jonggyu Baek; Kate L Lapane Journal: Drugs Aging Date: 2020-02 Impact factor: 3.923